NCT03778684

Brief Summary

Obesity has been associated with menstrual irregularities, chronic an-ovulation, infertility, and poor outcomes in women undergoing in vitro fertilization. There is strong evidence that obesity is associated with a higher n vitro fertilization cycle cancellation rate (despite administration of higher doses of exogenous gonadotrophins), a lower mature oocyte yield and lower number of cryopreservation cycles. Furthermore, obese women have been shown to have impaired response to ovarian stimulation and significantly lower live births after in vitro fertilization. Indeed, obesity affects many ovarian intra-follicular steroidogenic, metabolic and inflammatory pathways.This is particularly evident in women with abdominal (central obesity). Waist circumference measurement is used to identify individuals with abdominal obesity but it cannot differentiate between intra-abdominal fat and subcutaneous abdominal fat accumulation. The reliable measurement of visceral fat and subcutaneous fat is not only important as a tool to predict cardiovascular and metabolic disease risk, but it is also essential to evaluate the effect of these fat compartments on female reproductive function. Intra-abdominal fat accumulation is related to insulin resistance in women with polycystic ovary syndrome and in these women the resulting hyperinsulinemia contributes to an-ovulation. Obese anovulatory women with polycystic ovary syndrome who resume ovulation during a 6-month lifestyle program lose more visceral fat with no difference in the change of subcutaneous fat compared to the women who did not resume ovulation. Another recent study that enrolled 140 non-polycystic ovary syndrome in vitro fertilization women demonstrated that women with increased waist circumference and higher follicular fluid leptin have less oocytes fertilized and failed in vitro fertilization outcomes. Increased intra-abdominal fat during early pregnancy is associated with insulin resistance and increased diastolic blood pressure and it can predict glucose intolerance in later pregnancy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
88

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 16, 2018

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 19, 2018

Completed
1 month until next milestone

Study Start

First participant enrolled

February 1, 2019

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2022

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 26, 2022

Completed
Last Updated

November 30, 2022

Status Verified

November 1, 2022

Enrollment Period

3.1 years

First QC Date

December 16, 2018

Last Update Submit

November 26, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of women will be pregnant (clinical pregnancy rate)

    a pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy.

    1 month

Study Arms (2)

Normal Body mass index without central obesity

EXPERIMENTAL
Diagnostic Test: Visceral fat thicknessDiagnostic Test: Body mass index

High Body mass index with central obesity

EXPERIMENTAL
Diagnostic Test: Visceral fat thicknessDiagnostic Test: Body mass index

Interventions

Visceral fat thicknessDIAGNOSTIC_TEST

An initial longitudinal sweep will be done from the xiphoid process to the umbilicus to determine the area of maximum pre-peritoneal fat thickness.

High Body mass index with central obesityNormal Body mass index without central obesity
Body mass indexDIAGNOSTIC_TEST

Weight and height will be measured with subjects in a standing position wearing light clothes and no shoes.

High Body mass index with central obesityNormal Body mass index without central obesity

Eligibility Criteria

Age18 Years - 35 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age of women 18 - 35 yrs old.
  • Women with Body mass index I 18 - 35 kg/m2.
  • Infertile women with an indication for In vitro fertilization
  • Anticipated normal responders.
  • Normal uterine cavity by trans-vaginal ultrasound.

You may not qualify if:

  • Poly cystic ovarian syndrome
  • Diabetic patients.
  • Known Poor ovarian response
  • Patients with abnormal uterine cavity.
  • Refusal to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Women Health Hospital - Assiut university

Asyut, 71111, Egypt

Location

MeSH Terms

Conditions

Infertility

Interventions

Body Mass Index

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Intervention Hierarchy (Ancestors)

Body Weights and MeasuresBody ConstitutionPhysical ExaminationDiagnostic Techniques and ProceduresDiagnosisAnthropometryInvestigative TechniquesPhysiological PhenomenaBiometryEpidemiologic MeasurementsPublic HealthEnvironment and Public Health

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Lecturer

Study Record Dates

First Submitted

December 16, 2018

First Posted

December 19, 2018

Study Start

February 1, 2019

Primary Completion

March 1, 2022

Study Completion

November 26, 2022

Last Updated

November 30, 2022

Record last verified: 2022-11

Locations